- APOLLO-1 and APOLLO-2 Phase 3 efficacy trials of oliceridine remain on track for first quarter 2017 top-line data release. The APOLLO-1 trial includes patients suffering moderate to severe pain after undergoing bunionectomy, while the APOLLO-2 trial includes patients suffering moderate to severe pain after undergoing abdominoplasty; both are 375-patient, multicenter, randomized, double-blind, placebo- and active-controlled studies. Patients are randomized to receive placebo, morphine, or one of three oliceridine regimens, all dosed as needed via patient-controlled analgesia (PCA) device for the management of their post-operative pain, with approximately 75 patients per study arm. The primary objective of both trials is to evaluate the analgesic efficacy of oliceridine versus placebo. Secondary endpoints compare the efficacy, safety, and tolerability of oliceridine to morphine.
- Patient enrollment remains on track in the ATHENA multi-procedure safety study of oliceridine to support NDA filing in 2H 2017. This trial complements the APOLLO studies and aims to evaluate the safety and tolerability of oliceridine in patients with moderate to severe acute pain caused by a broad range of medical conditions or surgeries. Patients are treated on an as-needed basis via IV bolus, PCA administration, or both, as determined by the investigator.
- Continued engagement at pain medicine conferences. The Company gave or sponsored presentations at numerous medical conferences, including meetings of the American Society for Pain Management Nursing, American College of Surgeons, and American Society of Anesthesiologists (ASA). Two abstracts were selected for oral podium presentations at the ASA meeting.
- Hosted an investor webcast featuring presentations on acute pain management by leading clinicians. In October, the Company webcast a symposium in which leading clinicians provided their perspectives on the unmet needs associated with current injectable analgesics and how oliceridine may fit into the current treatment landscape for acute moderate to severe pain. A webcast replay is available at http://investors.trevena.com/events.cfm.
- TRV250 program on track for IND submission this year. TRV250 is a potential first-in-class medicine in preclinical development for the treatment of episodic migraine. It was designed to use a novel non-narcotic approach to treating migraine by selectively targeting the delta receptor. There are no approved drugs selectively targeting this receptor. The Company continues to expect to submit an investigational new drug application for TRV250 to the FDA by the end of 2016.
Cash, cash equivalents, and marketable securities totaled $119.6 million as of September 30, 2016, which Trevena continues to expect will be sufficient to fund its operations into 2018.About Trevena Trevena, Inc. is a biopharmaceutical Company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical needs. The Company has discovered four novel and differentiated drug candidates including oliceridine (TRV130), an FDA-designated Breakthrough Therapy currently in Phase 3 development for intravenous management of moderate-to-severe acute pain. Trevena has also discovered TRV250, in preclinical development for the treatment of migraine, as well as TRV734 for pain and TRV027 for acute heart failure. The Company also has an early stage portfolio of drug discovery programs. Cautionary Note on Forward Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company's clinical trials, including the expected timing of the release of top-line data from the APOLLO studies and the timing of the NDA filing for oliceridine; the uncertainties inherent in conducting clinical trials, including whether the Phase 3 studies will support the approval of oliceridine and any potential differentiation of oliceridine from conventional opioids; whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials; expectations for regulatory approvals, including for oliceridine; availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties related to the Company's intellectual property; other matters that could affect the availability or commercial potential of the Company's therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
|Condensed Statements of Operations|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|General and administrative||4,078,349||2,780,115||11,692,781||8,977,000|
|Research and development||25,548,532||9,650,138||58,504,964||30,524,601|
|Total operating expenses||29,626,881||12,430,253||70,197,745||39,501,601|
|Loss from operations||(29,626,881||)||(10,555,253||)||(66,447,745||)||(35,126,601||)|
|Other income (expense)||(271,775||)||(60,230||)||(446,208||)||62,622|
|Per share information:|
|Net loss per share of common stock, basic and diluted||($0.57||)||($0.24||)||($1.29||)||($0.85||)|
|Weighted average shares outstanding, basic and diluted||52,205,156||44,214,428||51,911,107||41,443,362|
|Condensed Balance Sheets|
|30-Sep-16||December 31, 2015|
|Cash and cash equivalents||$||25,228,034||$||46,773,566|
|Prepaid expenses and other current assets||1,644,792||1,892,217|
|Total current assets||121,258,832||174,530,230|
|Property and equipment, net||745,292||696,280|
|Intangible asset, net||13,438||14,844|
|Liabilities and stockholders' equity|
|Accrued expenses and other current liabilities||3,530,702||3,029,782|
|Current portion of loans payable, net||4,635,046||-|
|Total current liabilities||15,119,173||13,573,314|
|Loans payable, net||13,644,787||18,185,898|
|Capital leases, net of current portion||12,022||7,942|
|Deferred rent, net of current portion||200,666||238,917|
|Other long term liabilities||373,488||63,200|
|Additional paid-in capital||341,973,243||325,784,484|
|Accumulated other comprehensive income (loss)||55,917||(205,856||)|
|Total stockholders' equity||92,689,485||143,131,465|
|Total liabilities and stockholders' equity||$||122,130,182||$||175,353,974|